CRBU
NASDAQCaribou Biosciences Inc.
News25/Ratings12
News · 26 weeks35-25%
2025-10-262026-04-19
Mix2590d
- Insider14(56%)
- SEC Filings7(28%)
- Other4(16%)
Latest news
25 items- SECSEC Form PRE 14A filed by Caribou Biosciences Inc.PRE 14A - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECCaribou Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Caribou Biosciences, Inc. (0001619856) (Filer)
- PRCaribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve r/r MM patient cohort -- -- Ongoing dose expansion enrollment in CaMMouflage phase 1 clinical trial includes BCMA-naïve and BCMA-exposed cohorts; initial dose expansion and longer follow up on dose escalation data expected in 2026 -- BERKELEY, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medi
- SECSEC Form S-8 filed by Caribou Biosciences Inc.S-8 - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECSEC Form 10-K filed by Caribou Biosciences Inc.10-K - Caribou Biosciences, Inc. (0001619856) (Filer)
- SECCaribou Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Caribou Biosciences, Inc. (0001619856) (Filer)
- PRCaribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateBERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights. "2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs," said Rachel Haurwitz, PhD, Caribou's president and CEO. "The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this program is delivering on the prom
- INSIDERChief Technology Officer Kelly Timothy P sold $12,020 worth of shares (6,228 units at $1.93), decreasing direct ownership by 8% to 73,125 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- SECSEC Form 144 filed by Caribou Biosciences Inc.144 - Caribou Biosciences, Inc. (0001619856) (Subject)
- SECSEC Form 144 filed by Caribou Biosciences Inc.144 - Caribou Biosciences, Inc. (0001619856) (Subject)
- INSIDERChief Technology Officer Kelly Timothy P was granted 45,000 shares and sold $6,168 worth of shares (3,147 units at $1.96), increasing direct ownership by 112% to 79,353 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERChief Legal Officer Mcclung Barbara G was granted 45,000 shares and sold $13,598 worth of shares (6,938 units at $1.96), increasing direct ownership by 9% to 481,564 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERChief Business Officer Khan Ruhi Ahmad was granted 45,000 shares and sold $13,598 worth of shares (6,938 units at $1.96), increasing direct ownership by 57% to 104,998 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERChief Medical Officer Albertson Tina M. was granted 55,000 shares and sold $2,089 worth of shares (1,066 units at $1.96), increasing direct ownership by 370% to 68,523 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERSEC Form 4 filed by Director Richardson-Heron Dara4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson David Lee4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERSEC Form 4 filed by Director Sacks Natalie4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERSEC Form 4 filed by Director Zheng Ran4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERSEC Form 4 filed by Director Whiting Nancy4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERSEC Form 4 filed by Director Guggenhime Andrew4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERSEC Form 4 filed by Director Braunstein Scott4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERChief Financial Officer Ryali Sriram was granted 55,000 shares, increasing direct ownership by 317% to 72,360 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- INSIDERPresident and CEO Haurwitz Rachel E. was granted 151,700 shares, increasing direct ownership by 51% to 447,150 units (SEC Form 4)4 - Caribou Biosciences, Inc. (0001619856) (Issuer)
- PRCaribou Biosciences to Participate in Upcoming Investor ConferencesBERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: Citi 2026 Virtual Oncology Leadership Summit, VirtualFebruary 19, 2026, with a fireside chat at 10:45 AM ET Leerink Global Healthcare Conference, Miami, FLMarch 10, 2026, with a fireside chat at 8:00 AM ETWebcast For more information and link to the Leerink webcast, please visit the Events page on Caribou's website. The webcast will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Cari
- PRCaribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data demonstrate efficacy and durability that is on par with autologous CAR-T cell therapy in 2L LBCL patients CB-011 CaMMouflage phase 1 translational and clinical data correlate CAR-T cell expansion with deep, durable responses and support the regimen selected for dose expansion BERKELEY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced presentations at the 2026 Tandem